Compares iGlarLixi with standard care in adults with type 2 diabetes
Tests iGlarLixi against standard diabetes care in adults with poorly controlled type 2 diabetes.
Plain-language title generated from the registry record
Registry title: Efficacy and Safety of iGlarLixi Versus Standard of Care in a Real-world Adult China Population With Uncontrolled Type 2 Diabetes on Oral Agents
Key facts
- Where
- Changchun, Changsha, Hangzhou, Harbin, Hefei, Hengyang, Huizhou, Jiaxing, Nanchang, Nanjing, Ningbo, Shanghai, Shenzhen, Wuhan, and Xinxiang, ChinaSee the 24 sites
- Phase
- Phase 4
Where in China
- The First Clinical Hospital of Jilin Academy of Chinese Medicine SciencesChangchun, ChinaTaking people
- Hunan Provincial People's Hospital (The First Affiliated Hospital of Hunan Normal University)Changsha, ChinaTaking people
- Zhejiang Provincial People's HospitalHangzhou, ChinaTaking people
- Heilongjiang Provincial HospitalHarbin, ChinaTaking people
- The First Affiliated Hospital of Anhui Medical UniversityHefei, ChinaTaking people
- The First Affiliated Hospital of USTC(Anhui Provincial Hospital)Hefei, ChinaTaking people
- Affiliated Nanhua Hospital, University of South ChinaHengyang, ChinaTaking people
- Hengyang Central HospitalHengyang, ChinaTaking people
- The First People's Hospital of HuizhouHuizhou, ChinaTaking people
- Jiaxing First HospitalJiaxing, ChinaTaking people
- The Second Affiliated Hospital of Nanchang UniversityNanchang, ChinaTaking people
- The Second Affiliated Hospital of Nanjing Medical UniversityNanjing, ChinaTaking people
- Ningbo Medical Center Lihuili HospitalNingbo, ChinaTaking people
- Ningbo No.2 HospitalNingbo, ChinaTaking people
- Minhang Hospital, Fudan University / Central Hospital of Minhang District, ShanghaiShanghai, ChinaTaking people
- Shanghai East Hospital, Tongji UniversityShanghai, ChinaTaking people
- Shanghai Pudong New Area Punan HospitalShanghai, ChinaTaking people
- Shanghai Qingpu District Central Hospital / Qingpu Branch of Zhongshan Hospital, Fudan UniversityShanghai, ChinaTaking people
- Shanghai Tenth People's Hospital / Tenth People's Hospital of Tongji UniversityShanghai, ChinaTaking people
- Shanghai Tongren Hospital, Shanghai Jiao Tong University School of MedicineShanghai, ChinaTaking people
- Zhongshan Hospital,Fudan UniversityShanghai, ChinaTaking people
- Shenzhen Third People's HospitalShenzhen, ChinaTaking people
- Wuhan Fourth Hospital / Wuhan Puai HospitalWuhan, ChinaTaking people
- Xinxiang Central HospitalXinxiang, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Shanghai Zhongshan Hospital
- Trial code
- NCT07307235
- Record updated
- 7 July 2026
- Original description
This study is a prospective, open-label, multicenter, parallel-group, positive-controlled, and pragmatic randomized clinical trial (pRCT). It will compare the efficacy and safety of iGlarLixi versus standard of care in adult T2DM patients with poor glycemic control, who are using 1 to 3 OADs in a real-world clinical practice setting. A total of 1,316 subjects from approximately 40 research centers in China will be randomly assigned in a 1:1 ratio to one of the following treatment groups: Group 1: iGlarLixi for blood glucose control; and Group 2: Standard of care for diabetes (basal insulin or premixed insulin, excluding any GLP-1RA-containing drugs). Considering the substantial difference in intervention methods between the two groups, the study is designed as non-blinded with an open-label approach.Read full original descriptionShow less
Efficacy and Safety of iGlarLixi Versus Standard of Care in a Real-world Adult China Population With Uncontrolled Type 2 Diabetes on Oral Agents-a Pragmatic Randomized Controlled Trial
This study is a prospective, open-label, multicenter, parallel-group, positive-controlled, and pragmatic randomized clinical trial (pRCT). It will compare the efficacy and safety of iGlarLixi versus standard of care in adult T2DM patients with poor glycemic control, who are using 1 to 3 OADs in a real-world clinical practice setting. A total of 1,316 subjects from approximately 40 research centers in China will be randomly assigned in a 1:1 ratio to one of the following treatment groups: Group 1: iGlarLixi for blood glucose control; and Group 2: Standard of care for diabetes (basal insulin or premixed insulin, excluding any GLP-1RA-containing drugs). Considering the substantial difference in intervention methods between the two groups, the study is designed as non-blinded with an open-label approach.
Inclusion: Participant must be at least 18 of age inclusive, at the time of signing the informed consent; Type 2 diabetes mellitus diagnosis; Participants who are treated for at least 3 months prior to the screening visit with an adequate dose of 1-3 OADs; HbA1c 7.5-11%; Further intensification with an additional antidiabetic injectable medication is indicated to achieve glycaemic target at the discretion of the study physician according to approval labelling; Participants who have signed informed consent form (ICF).
Exclusion: Treatment with more than 3 oral antidiabetic medications, or any injectable medication in a period of 30 days before the day of eligibility assessment. Temporary/emergency use of insulin is allowed, as is prior insulin treatment for gestational diabetes; Participants who involved in other clinical trial within 3 months prior to the time of screening visit; Conditions/situations such as:; Participant with short life expectancy. Participant with conditions/concomitant diseases making him/her not evaluable for the primary efficacy endpoint (eg, hemoglobinopathy or hemolytic anemia, receipt of blood or plasma products within 3 months prior to screening); Participant with conditions/concomitant diseases precluding his/her safe participation in this study (eg, active malignant tumor, major systemic diseases, presence of clinically significant diabetic retinopathy or presence of macular edema likely to require laser treatment within the study period); Uncooperative or any condition that could make the participant potentially non-compliant to the study procedures; Any clinically significant abnormality identified on physical examination, laboratory tests, or vital signs at the time of screening, or any major systemic disease resulting in short life expectancy that in the opinion of the Investigator would restrict or limit the patient's successful participation for the duration of the study; Participant who has a severe renal function impairment with an estimated glomerular filtration rate (eGFR) <30 mL/min/1.73m2; Diagnosed with T1DM; BMI <20 kg/m2 or BMI ≥40 kg/m2; Contraindications to iGlarLixi according to the China NMPA approved label; Pregnant or breast-feeding woman; Woman of childbearing potential not protected by highly effective contraceptive method of birth control and/or who is unwilling or unable to be tested for pregnancy.